MEMBRANE-BOUND SOLUBLE IL-2 RECEPTOR (IL-2R) AND LEVELS OF IL-1-ALPHA, IL-2, AND IL-6 IN THE SERUM AND IN THE PBMC CULTURE SUPERNATANTS FROM 17 PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

被引:0
|
作者
MANTOVANI, G [1 ]
MACCIO, A [1 ]
LAI, P [1 ]
GHIANI, M [1 ]
TURNU, E [1 ]
DELGIACCO, GS [1 ]
机构
[1] UNIV CAGLIARI,DEPT MED ONCOL,I-09124 CAGLIARI,ITALY
来源
CELL BIOPHYSICS | 1995年 / 27卷 / 01期
关键词
HEMATOLOGICAL MALIGNANCIES; INTERLEUKIN-1; INTERLEUKIN-2; RECEPTOR; INTERLEUKIN-6; PERIPHERAL BLOOD MONONUCLEAR CELLS; SOLUBLE INTERLEUKIN-2 RECEPTOR;
D O I
暂无
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
The present study investigated the peripheral blood mononuclear cells (PBMC) blastic responses to PHA, PHA plus recombinant IL-2 (rIL-2) and rIL-2 alone; the expression of membrane-bound IL-2R on PHA-stimulated PBMC and the levels of IL-1 alpha, IL-2, IL-6, and sIL-2R in serum and in culture supernatants from PHA-stimulated PBMC in 17 patients with hematological malignancies (mean age 58.5 yr, range 22-82): 6 with non-Hodgkin's lymphoma (NHL), 4 with Hodgkin's lymphoma (HL), 5 with Hairy cell leukemia, 1 with chronic myelogenous leukemia, and 1 with chronic lymphocytic leukemia. The patients with Ht and NHL with active disease (AD) were separated from those in clinical remission. The patients with AD were studied at diagnosis (obviously before therapy) and the patients in clinical remission were out of therapy since at least 6 mo. The lymphocyte blastogenic response to PHA was significantly lower in patients with HL and NHL with AD than in the control group. The response to rIL-2 alone was in the same range in the control group and in HL and NHL AD patients. By adding rIL-2 to PHA there was an increase of the blastogenic response of the same patients. The percentage of CD25 expressed on PHA-stimulated lymphocytes from patients with HL and NHL AD and from normal subjects is in the same range. Serum levels of IL-2, IL-6, and sIL-2R were significantly higher in HL and NHL AD patients than in controls as well as in all other hematological malignancies. Supernatants derived from PHA-stimulated PBMC were assessed for the presence of cytokines and sIL-2R by ELISA. The levels of IL-2, IL-6, and sIL-2R were significantly lower in HL and NHL AD patients than in controls as well as in all other hematological malignancies.
引用
收藏
页码:1 / 14
页数:14
相关论文
共 50 条
  • [11] 子宫肌瘤与血清IL-2、IL-2R、IL-6关系研究
    王艳
    当代医学, 2013, 19 (25) : 62 - 62
  • [12] Serum IL-1β, IL-2, IL-6, and IL-8 Levels in Schizophrenia Subtypes
    Kuloglu, Murat
    Bayik, Yilmaz
    Unal, Ahmet
    Gecici, Omer
    Ustundag, Bilal
    KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, 2011, 21 (03): : 193 - 200
  • [13] The role of IL-2 and soluble IL-2R in depression and antidepressant response
    Eller, Triin
    Vasar, Veiko
    Shlik, Jakov
    Maron, Eduard
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2009, 10 (07) : 638 - 643
  • [14] IL-2Rα on one cell can present IL-2 to IL-2Rβ/γc on another cell to augment IL-2 signaling
    Eicher, DM
    Waldmann, TA
    JOURNAL OF IMMUNOLOGY, 1998, 161 (10): : 5430 - 5437
  • [15] Serum levels of soluble IL-2 receptor α, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration
    Akiyama, K
    SCHIZOPHRENIA RESEARCH, 1999, 37 (01) : 97 - 106
  • [16] ‘IL-2Rα-biased’ IL-2 for cancer immunotherapy
    Nature Cancer, 2023, 4 : 1222 - 1223
  • [17] 'IL-2Rα-biased' IL-2 for cancer immunotherapy
    He, Kaijie
    NATURE CANCER, 2023, 4 (09) : 1222 - 1223
  • [18] CORONARY SINUS SAMPLING OF IL-2, IL-2 RECEPTOR, AND IL-6 AFTER CARDIAC TRANSPLANTATION
    FYFE, AI
    DALY, PA
    GALLIGAN, L
    FEINDEL, CM
    CARDELLA, CJ
    CIRCULATION, 1990, 82 (04) : 629 - 629
  • [19] RELATIONSHIP OF IL-2, IL-2R (CD25(+)), SOLUBLE IL-2R AND IL-4 WITH DISEASE-ACTIVITY IN SLE PATIENTS
    CUADRADO, MJ
    MARUBAYASHI, M
    ORTEGA, C
    FERNANDEZARCAS, N
    GARCIACOZAR, F
    PENA, J
    SANCHEZGUIJO, P
    SANTAMARIA, M
    LUPUS, 1993, 2 (04) : 257 - 260
  • [20] 17-β-estradiol suppresses IL-2 and IL-2 receptor
    McMurray, RW
    Ndebele, K
    Hardy, KJ
    Jenkins, JK
    CYTOKINE, 2001, 14 (06) : 324 - 333